LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.

Publication

Author(s):

Pour SM, Woolley I, Canavan P, Chuah J, Russell DB, Law M, Petoumenos K.

Pub Title:

Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.

Pub Date:

Sep 30 2011

Pub Region(s):

Asia-Pacific

Journal Issue:

3

Page Number:
295-303

Journal:

Title: 
Sexual Health
Link: 
http://www.publish.csiro.au/index.cfm?paper=SH10008

PubMed: 21851768
Pub PDF:

Abstract
BACKGROUND
: Patients who have become triple class experienced (TCE) are at a high risk of exhausting available treatment options. This study aims to investigate factors associated with becoming TCE and to explore the effect of becoming TCE on survival. We also project the prevalence of TCE in Australia to 2012.

METHODS: Patients were defined as TCE when they stopped a combination antiretroviral treatment (cART) that introduced the third of the three major antiretroviral classes. Cox proportional hazards models were used to investigate factors associated with TCE and the effect of TCE on survival. To project TCE prevalence, we used predicted rates of TCE by fitting a Poisson regression model, together with the estimated number of patients who started cART in each year in Australia, assuming a mortality rate of 1.5 per 100 person-years.

RESULTS: Of the 1498 eligible patients, 526 became TCE. Independent predictors of a higher risk of TCE included current CD4 counts below 200cellsμL(-1) and earlier calendar periods. No significant difference in survival was observed between those who were TCE and those who were not yet TCE. An increasing number of patients are using cART in Australia and if current trends continue, the number of patients who are TCE is estimated to increase from 2800 in 2003 to 5000 in 2012.

CONCLUSION: Our results suggest that the prevalence of TCE in Australia is estimated to plateau after 2003. However, as an increasing number of patients are becoming TCE, it is necessary to develop new drugs that come from new classes or do not have overlapping resistance.

PMID: 21851768 [PubMed - indexed for MEDLINE]

PMCID: PMC3332145

 
The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Pour SM, Woolley I, Canavan P, Chuah J, Russell DB, Law M, Petoumenos K. Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections. Sex Health. 2011 Sep;8(3):295-303. doi: 10.1071/SH10008. PubMed PMID: 21851768; PubMed Central PMCID: PMC3332145.